Sanj Patel, CEO & Chairman of the Board, stated that "Year-to-date, in 2025, we've continued to execute and meaningfully advance our commercial business and clinical development portfolio." He ...
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by ...
– ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 million – – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results